Latest Rituximab Stories
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.
The promising investigational targeted therapy ibrutinib and its mechanism of silencing gene communication pathways critical to the development of cancer may be an effective way to combat chronic lymphocytic leukemia (CLL).
Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease.
Each year an estimated 70,000 people globally are diagnosed with the kidney immune disorder, idiopathic membranous nephropathy (IMN). Idiopathic membranous nephropathy (IMN) can eventually lead to kidney failure.
- The analysis of literature, focusing on the words and grammar to the exclusion of context or literary merit.